Actemra solution for subcutaneous injection
Actemra 170613 1 Consumer Medicine Information . Actemra ® solution for subcutaneous injection . Tocilizumab . 162 mg/0.9 mL solution for subcutaneous injection
Download Actemra solution for subcutaneous injection
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
How to administer intramuscular and subcutaneous vaccine ...
www.immunize.orgHow to Administer Intramuscular and Subcutaneous Vaccine Injections . Administer these vaccines . via IM route • Diphtheria-tetanus-pertussis (DTaP,
How to administer intramuscular and subcutaneous vaccines ...
www.immunize.orgTitle: How to administer intramuscular and subcutaneous vaccines to adults Keywords: vaccine administration, giving vaccines to adults, administering vaccines to adults, intramusclar and subcutaneous vaccine injections, im and sc, P2020a
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzZoladex 10.8 mg Data Sheet 280218 Copyright 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME ZOLADEX 10.8 mg Depot Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ...
Guidelines for the Use of Subcutaneous Medications in ...
www.nhslanarkshire.org.uk5 1. Rationale and indications When the oral route is unavailable to patients the subcutaneous (SC) route is the preferred method of drug administration.
SOFT TISSUE INFECTIONS - Practical Plastic Surgery
www.practicalplasticsurgery.orgSoft Tissue Infections 185 Cuts from glass and punctures from metal objects should raise concern about the presence of a foreign body in the soft tissues.
CharaCterization of DermatologiCal lesions by UltrasoUnD
www.webcir.org4008 Characterization of Dermatological lesions by Ultrasound gonzlez C. revie articles Figure 3. Ultrasound appearance of the epidermal cyst with an oval configuration, hypoechoic, and a marked posterior acoustic